Chemerin-9
- Category
- Weight Management & Metabolic
- Regulatory status
- Not FDA-approved
A 9-amino-acid fragment of the adipokine chemerin, marketed for immune modulation, fat metabolism, and antimicrobial skin effects via the ChemR23 receptor. The case rests on mechanism and cell studies only, with no controlled human trials, and even those effects are rated low confidence or speculative. There is no human safety data, and a pro-inflammatory effect at high doses is unresolved. Not an approved drug, sold as unregulated research-grade material.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Chemerin-9 (also called C9) is a bioactive nonapeptide (9-amino-acid peptide) derived from the C-terminal region of chemerin, a 163-amino-acid precursor protein encoded by the RARRES2 (retinoic acid receptor responder protein 2) gene. Chemerin-9 corresponds to residues 149-157 of prochemerin and is the minimal peptide fragment that retains full agonist activity at the chemokine-like receptor 1 (CMKLR1, also known as ChemR23). This receptor belongs to the Gi-coupled chemoattractant GPCR family and mediates chemerin's diverse biological functions.
Chemerin itself is an adipokine and immune mediator with roles spanning inflammation, metabolism, and antimicrobial defense. It is produced by adipocytes, hepatocytes, and skin keratinocytes, and acts as a chemoattractant for dendritic cells, macrophages, and NK cells expressing CMKLR1. The cited antimicrobial evidence concerns p4, not chemerin-9. Research has shown that chemerin-derived peptides account for a significant portion of the bactericidal activity in human skin exudates.
Chemerin-9 is currently a research-stage peptide with no clinical trials or approved therapeutic applications. Its interest lies in its CMKLR1 signaling properties, its role in metabolic regulation (linking adiposity to inflammation and insulin resistance), and emerging structural biology work that has elucidated its receptor binding mechanism at atomic resolution. It represents an early-stage but scientifically fascinating peptide target.
How it works in the body
A 9-amino-acid bioactive fragment of the adipokine chemerin that signals through the ChemR23 (CMKLR1) receptor. It recruits immune cells (macrophages, dendritic cells, NK cells) to sites of inflammation and modulates adipocyte differentiation and glucose uptake.
Research overview
Chemerin-9 research is primarily in the preclinical/basic science phase. The peptide has been studied for its signaling through CMKLR1, with key structural work reported in 2023 by Zhang et al. (PMC10274904, a bioRxiv preprint subsequently published in PLOS Biology) providing the cryo-EM structure of the CMKLR1-Gi complex with chemerin-9, revealing atomic-level details of receptor activation. Earlier work by Zhou et al. (Acta Pharmacol Sin 2014) characterized chemerin-9-induced receptor internalization via clathrin-independent mechanisms. The antimicrobial research is particularly noteworthy — Godlewska et al. (2019, PMC6349111) studied antimicrobial p4, a separate 20-residue fragment spanning residues 66–85. The killing mechanism involves homodimerization facilitated by the oxidative skin surface environment and damage to the bacterial cytochrome bc1 complex. Chemerin levels have been associated with obesity, metabolic syndrome, and insulin resistance in observational studies. No human clinical trials of chemerin-9 itself have been conducted.
Who researches Chemerin-9?
Commonly researched by
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(3)
Rated by level of concern
No human safety data available
HighClinicalTrials.gov API v2 query 'chemerin-9' — totalCount 0 July 2026
Potential pro-inflammatory effects at high concentrations
ModeratePMC10274904 (Structural basis of CMKLR1 signaling induced by chemerin9 — bioRxiv PREPRINT 2023, not peer-reviewed at time of citation; reports reduced CD206/CD163); PMID 18391062 (Cash 2008 — C15's reduced chemoattractant activity, by contrast)
Metabolic effects uncertain
ModeratePMC4327305 (PeerJ 2015 — agonists beneficial in rodents/adipocytes); PMID 34330814 (Sci Immunol 2021 — chemerin-CMKLR1 limits thermogenesis via beige/IL-33 circuit; erratum PMID 42030374); PMID 41457200, doi:10.1007/s11906-025-01354-3 (Chemerin as a Mediator of Hypertension and Cardiometabolic Diseases, Curr Hypertens Rep 2025;28(1):4)
Interaction summary(8)
Rated by direction with this peptide
Antihypertensive drugs (ACE inhibitors, ARBs, calcium channel blockers, diuretics)
CautionModerateChemerin-9 is a direct CMKLR1-mediated vasoconstrictor — it contracted human saphenous vein (pD2 7.30) and human resistance arteries (pD2 7.05) ex vivo and raised mean arterial pressure by 9.1 +/- 1.0 mmHg in normotensive rats at 200 nmol — so it could blunt antihypertensive control. Rated Moderate because this is the best-evidenced chemerin-9 effect and the only one shown in human tissue; it remains ex vivo/rodent, with no human dosing.
PMID 27742615 / PMC5121526 (Kennedy et al., J Am Heart Assoc 2016;5(10):e004421 — human vessel contraction and 9.1 mmHg rat MAP rise at 200 nmol, blocked by CCX832)
Pulmonary arterial hypertension therapies (PDE5 inhibitors, endothelin antagonists, prostacyclin analogs)
CautionLowChemerin-9-induced pulmonary artery contraction is enhanced in monocrotaline PAH rats through upregulation of smooth-muscle CMKLR1, so the vasoconstrictor liability may be disproportionately greater in the population these drugs treat. This is isolated-artery data from a single rodent PAH model, with no human tissue or human dosing evidence.
PMID 31965243 (Yamamoto et al., Pflugers Arch 2020 — chemerin-9-induced contraction enhanced via smooth-muscle CMKLR1 upregulation in PAH rat pulmonary artery).
Centrally acting sympatholytics and beta-blockers (clonidine, moxonidine, metoprolol)
CautionTheoreticalAcute intracerebroventricular chemerin-9 raised systemic blood pressure in rats by activating sympathetic nerves via CMKLR1 in the brain, so central CMKLR1 agonism is mechanistically opposed to sympatholytic therapy — though the route was ICV in rodents, not systemic dosing.
PMID 32462328 (Yamamoto et al., Pflugers Arch 2020 — acute ICV chemerin-9 increases systemic blood pressure through sympathetic activation via CMKLR1 in brain).
CMKLR1/ChemR23 antagonists (e.g. CCX832, alpha-NETA — research compounds)
NeutralLowDirect pharmacodynamic antagonism: CCX832 abolished chemerin-9's in vitro vascular and in vivo pressor actions, so co-exposure cancels chemerin-9's effects rather than producing toxicity.
PMID 27742615 / PMC5121526 (Kennedy et al., JAHA 2016 — CCX832 blocked both in vitro and in vivo chemerin-9 vascular actions)
Insulin and insulin-sensitizing antidiabetics (metformin, thiazolidinediones)
SynergisticTheoreticalChemerin and its C-terminal peptide C15 sensitise adipocytes to insulin-stimulated glucose uptake, and chemerin-9 lowered glucose and HOMA-IR in a rodent pancreatogenic-diabetes model, raising a plausible additive glucose-lowering effect. Entirely preclinical with no human confirmation; note the adipocyte work used C15, not chemerin-9, so the read-across is indirect.
PMC4327305 (Goralski et al., PeerJ 2015;3:e753 — chemerin/C15 in adipocytes and rodents); PMID 32020208 / PMC7002998 (chemerin-9 in pancreatogenic diabetes, Mol Med Rep 2020)
Resolvin E1 and omega-3 / SPM-based therapies
CautionTheoreticalResolvin E1 is an endogenous pro-resolving agonist at the same ChemR23/CMKLR1 receptor, so a high-occupancy synthetic full agonist like chemerin-9 could compete for the receptor and shift signaling toward the chemotactic rather than pro-resolving output. This is receptor-sharing logic, not a demonstrated interaction — no co-administration study exists.
PMID 15753205 (Arita et al., J Exp Med 2005;201:713-22 — RvE1 acts through ChemR23)
Immunosuppressants and anti-inflammatory biologics (corticosteroids, TNF inhibitors, calcineurin inhibitors)
CautionTheoreticalChemerin-9 activates CMKLR1, the receptor through which chemerin recruits antigen-presenting cells, and chemerin9 pushed primary human macrophages away from the CD206/CD163 reparative phenotype — mechanistically opposed to the intent of immunosuppressive therapy. No co-administration study exists, and the macrophage data are from a preprint.
PMID 14701797 (C9 activates CMKLR1); PMID 14530373 (chemerin recruits antigen-presenting cells, J Exp Med 2003); PMC10274904 (bioRxiv preprint 2023 — CD206/CD163 reduction)
Topical antibiotics / host-defense peptides (LL-37) for skin infection
NeutralTheoreticalThe additive antibacterial effect with LL-37 was shown for the chemerin p4 fragment (Val66-Pro85) at sublethal concentrations, not for chemerin-9. There is no evidence chemerin-9 contributes antimicrobial synergy and it should not be assumed to substitute for p4. This entry documents the absence of an interaction rather than a demonstrated one.
PMID 30504221 (J Biol Chem 2019); PMID 34691000 / PMC8595592 (Front Microbiol 2021 — p4 additive with LL-37)
Known risks(3)
No human safety data available
Chemerin-9 has never been administered to humans. No safety, tolerability, or toxicology data exist from human studies. All available data is from in-vitro cell culture and animal models.
Potential pro-inflammatory effects at high concentrations
TheoreticalWhile chemerin has anti-inflammatory properties at physiological levels, excessive CMKLR1 activation could theoretically promote inflammatory cell recruitment and exacerbate certain inflammatory conditions. The dose-response relationship in vivo is not well characterized.
Metabolic effects uncertain
TheoreticalGiven chemerin's association with insulin resistance and adipose tissue dysfunction, exogenous chemerin-9 could theoretically worsen metabolic parameters. However, the relationship between circulating chemerin levels and metabolic disease is complex and may not be straightforwardly causal.
Drug interactions(2)
Anti-inflammatory agents (NSAIDs, corticosteroids)
Theoretical interaction — chemerin-9 activates immune cell recruitment via CMKLR1, which could be modulated by anti-inflammatory drugs. No clinical data.
Immunosuppressants
Chemerin-9 promotes chemotaxis of dendritic cells and macrophages. Immunosuppressants could blunt this effect. No interaction data available.
Research & benefits
Evidence base
- Evidence Level
- Early Research (Preclinical Only, No Human Trials)
- Total Studies
- 100
- Human Studies
- 0
Chemerin-9 is purely a research peptide with no human clinical trials. All evidence comes from in-vitro cell culture, structural biology (cryo-EM), and animal models. The cited antimicrobial skin-infection findings concern p4, not chemerin-9. Metabolic associations come from observational human studies measuring circulating chemerin levels, not from chemerin-9 administration. The structural and mechanistic understanding is strong, but therapeutic translation is in very early stages.
Researched for(3)
Rated by confidence in the evidence
Chemoattractant for immune cells (dendritic cells, macrophages, NK cells) via CMKLR1
LowDocumented mainly for full-length chemerin in vitro and in mice, not this fragment in humans.
PMID 14701797 (Wittamer et al., J Biol Chem 2004;279:9956-62 — C9 chemotaxis, low nM); PMID 14530373 (Wittamer et al., J Exp Med 2003 — chemerin recruits antigen-presenting cells); PMC10274904 (Structural basis of CMKLR1 signaling induced by chemerin9 — bioRxiv preprint 2023, macrophage phenotype)
Full agonist activity at CMKLR1 — minimal functional fragment for receptor activation
LowReceptor binding and activation are well characterized structurally, with no demonstrated human benefit.
PMID 14701797; PMID 36881626, doi:10.1073/pnas.2214324120 (cryo-EM human CMKLR1-Gi bound to chemerin C-terminal nonapeptide, PNAS 2023); PMC4075970 (C9-induced clathrin-independent receptor internalization, Acta Pharmacol Sin 2014); PMC10274904 (bioRxiv preprint 2023)
Regulation of adipogenesis and energy metabolism through CMKLR1 in adipose tissue
LowAnimal and cell studies show metabolic effects via this receptor; human data are lacking.
PMC4327305 (Goralski et al., PeerJ 2015 — CMKLR1 agonists in rodents/adipocytes; peptide tested was C15); PMID 32020208 / PMC7002998 (chemerin-9 in pancreatogenic diabetes, Mol Med Rep 2020); PMID 34330814 (chemerin-CMKLR1 axis limits thermogenesis via beige adipocyte/IL-33 circuit, Sci Immunol 2021 — see 2026 erratum PMID 42030374)
Benefits(4)
Chemoattractant for immune cells (dendritic cells, macrophages, NK cells) via CMKLR1
Wittamer et al., J Exp Med 2003 (PMID 14530373); this study concerns chemerin rather than clinical administration of chemerin-9.
Full agonist activity at CMKLR1 — minimal functional fragment for receptor activation
Zhang et al., bioRxiv 2023 (PMC10274904) — structural study; final publication in PLOS Biology
Regulation of adipogenesis and energy metabolism through CMKLR1 in adipose tissue
Goralski et al., J Biol Chem 2007 (PMID 17635925); this study concerns chemerin and CMKLR1, not a demonstrated human benefit of chemerin-9.
Anti-inflammatory properties via resolution of inflammation pathways
Cash et al., J Exp Med 2008 (PMID 18362171); chemerin resolvin-like activity
Key studies(3)
Structural basis of CMKLR1 signaling induced by chemerin9
Structural Biology (Cryo-EM)N/A (structural study)Zhang X, Weiß T, Cheng MH, et al.
bioRxiv (preprint)
2023
The study resolved the chemerin-9–CMKLR1–Gi complex at 2.94 angstrom resolution and described an S-shaped peptide binding conformation. Provides atomic-level basis for understanding chemerin signaling and drug design.
The antimicrobial activity of chemerin-derived peptide p4 requires oxidative conditions to promote homodimerization
Preclinical (in-vitro + in-vivo mouse model)N/A (preclinical)Godlewska U, Bilska B, Zegar A, et al.
Journal of Biological Chemistry
2019
Chemerin-derived peptide p4 kills MRSA and suppresses microbial growth in topical skin infection model. Homodimerization via disulfide bridges (favored by oxidative skin surface conditions) is required for maximal bactericidal activity. Mechanism involves damage to bacterial cytochrome bc1 complex.
Chemerin C9 peptide induces receptor internalization through a clathrin-independent pathway
In-vitro cell biologyN/A (cell culture)Zhou JX, Liao D, Zhang S, Cheng N, He HQ, Ye RD
Acta Pharmacologica Sinica
2014
Chemerin-9 induces dose-dependent CMKLR1 internalization (up to 90% at 1 umol/L) via a clathrin-independent mechanism. Phosphorylation at Ser343 (GRK) and Ser347 (PKC) required for internalization. Loss of internalization enhanced receptor signaling (increased Ca2+ flux and ERK phosphorylation).
Regulation & availability
Why researchers look at it
Chemerin-9 is studied in metabolic disease and structural GPCR biology. CMKLR1 pharmacology makes chemerin-9 a research tool; p4's antimicrobial findings cannot be attributed to it.
- FDA status
- Chemerin-9 is not FDA-approved and is not eligible for compounding in the US.
- WADA status
- Not named individually, but prohibited at all times under WADA's 2026 S0 rule when used as an unapproved pharmacological substance. A demonstrated performance-enhancing effect is not required for S0 coverage.
- Prescribability
- No; not approved for any clinical use
- Availability
- Typical research quantities are milligram-scale. Custom synthesis is available from peptide contract manufacturers. No pharmaceutical-grade clinical formulation exists.
International status
EU
Not approved
US
Not FDA-approved
Worldwide
No regulatory approval in any jurisdiction
Regulatory timeline(6)
- 2003Chemerin identified as the endogenous ligand for CMKLR1/ChemR23 receptor (Wittamer et al., J Exp Med)
- 2007Chemerin characterized as an adipokine regulating adipogenesis (Goralski et al., J Biol Chem)
- 2014Chemerin C9 receptor internalization mechanism characterized (Zhou et al., Acta Pharmacol Sin)
- 2019Antimicrobial p4 findings published (Godlewska et al., J Biol Chem); p4 is distinct from chemerin-9.
- 2023Zhang et al. reported a chemerin-9–CMKLR1–Gi structure in bioRxiv, followed by publication in PLOS Biology.
- 2026Chemerin-9 remains a research tool; no clinical development programs announced
Sources & FAQs
Research sources(5)
- Zhang X et al. — CMKLR1 Cryo-EM Structure with Chemerin-9 (bioRxiv preprint, 2023)
- Godlewska U et al. — Antimicrobial Activity of Chemerin p4 (J Biol Chem 2019)
- Zhou JX et al. — Chemerin C9 Receptor Internalization (Acta Pharmacol Sin 2014)
- Wittamer V et al. — Chemerin as CMKLR1 Ligand (J Exp Med 2003)
- Goralski KB et al. — Chemerin as Adipokine (J Biol Chem 2007)
Frequently asked questions(3)
What is the relationship between chemerin and chemerin-9?
Chemerin is a 163-amino-acid precursor protein that is cleaved to produce its active forms. Chemerin-9 (C9) is a 9-amino-acid peptide fragment (residues 149-157) that retains full agonist activity at the CMKLR1 receptor. It is the smallest peptide that can fully activate the receptor, making it a valuable research tool.
Can chemerin-9 be used to treat infections?
The cited antimicrobial findings concern p4, a separate chemerin fragment; they do not establish chemerin-9 efficacy against infections. No human clinical trials have tested chemerin-9 for infection treatment. Significant development would be needed before any clinical use.
Is chemerin-9 related to obesity?
Chemerin (the full protein) is an adipokine produced by fat cells and is associated with obesity and metabolic syndrome — elevated circulating chemerin levels correlate with higher BMI, insulin resistance, and metabolic dysfunction. However, chemerin-9 as a therapeutic for obesity has not been tested. The metabolic associations are observational.